Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT05168566
Trial Phases:	Phase II	Protocol IDs:	SZCT-2020-06 (primary) NCI-2022-04928
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Teligene US
NCI Full Details:	http://clinicaltrials.gov/show/NCT05168566

Summary

This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of
Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon
EGFR Mutations Only, Including L861Q, G719X, and/or S768I)

Objectives

Sutetinib is an investigational irreversible EGFR tyrosine kinase inhibitor. EGFR is a
gene that makes a protein that is involved in cell growth and cell survival. Mutated
(changed) forms of the EGFR gene and protein have been found in some types of cancer,
including non-small cell lung cancer. These changes may cause cancer cells to grow and
spread in the body. The purpose of this study is to explore how effective Sutetinib
maleate capsules are for the treatment of patients with locally advanced or metastatic
NSCLC with non-resistant uncommon EGFR mutations

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.